more

Ascendis Pharma (ASND)

(Real Time Quote from BATS)

$127.72 USD

-8.81 (-6.45%)

Updated Aug 2, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

Top 35% (88 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?

by Zacks Equity Research Published on March 17,2023

Omega Therapeutics, Inc. (OMGA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Does Ascendis Pharma AS (ASND) Have the Potential to Rally 35% as Wall Street Analysts Expect?

by Zacks Equity Research Published on October 12,2022

The consensus price target hints at a 34.6% upside potential for Ascendis Pharma AS (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ASNDNegative Net Change

Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?

by Zacks Equity Research Published on July 15,2022

Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.

Why Ascendis Pharma (ASND) Might Surprise This Earnings Season

by Zacks Equity Research Published on May 11,2022

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ASNDNegative Net Change

Why Encompass Health (EHC) is Down 2.4% Since Q1 Earnings Beat

by Zacks Equity Research Published on May 10,2022

Encompass Health Corporation (EHC) looks to unveil eight additional de novo locations this year and increase its bed count.

Vermilion Energy (VET) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on May 10,2022

A favorable commodity pricing scenario is likely to have aided Vermilion Energy's (VET) earnings in Q1.

Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why

by Zacks Equity Research Published on May 09,2022

Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.

Ring Energy (REI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on May 09,2022

A favorable commodity pricing scenario is likely to have aided Ring Energy's (REI) earnings in Q1.

oil-energy

Should You Buy Ascendis Pharma (ASND) Ahead of Earnings?

by Aditi Saraogi Published on March 03,2022

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ASNDNegative Net Change

Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains?

by Zacks Equity Research Published on January 25,2022

Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ASNDNegative Net Change

Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA

by Zacks Equity Research Published on January 24,2022

The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.

Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD

by Zacks Equity Research Published on January 14,2022

Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.

Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing

by Zacks Equity Research Published on November 15,2021

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

biotechs

AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research Published on November 09,2021

AstraZeneca's(AZN) third-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on sales numbers of AstraZeneca's COVID-19 vaccine.

pharmaceuticals

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

by Zacks Equity Research Published on November 08,2021

On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

biotechs

Organon (OGN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research Published on November 08,2021

Organon (OGN) is set to provide updates on its earnings and revenues when it reports third-quarter 2021 results.

pharmaceuticals

Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

by Zacks Equity Research Published on September 08,2021

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

biotechs

Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

by Zacks Equity Research Published on August 27,2021

Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.